Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.
You may also be interested in...
Celgene Secures Revlimid Frontline Myeloma Approval
Labeling includes new warning for development of second primary malignancies and more language about other kinds of adverse events, but there is already widespread off-label use and analysts don’t expect the warnings to have much impact.
Celgene’s Otezla Grabs New Psoriatic Arthritis Patients As Launch Accelerates
Celgene reports its apremilast is attracting more new psoriatic arthritis patients than branded leaders in the space. Sales for its first full quarter amounted to $18 million and new indication in psoriasis should start to contribute later this year, company says.
Celgene’s Budding Blockbuster Abraxane Scoops Pancreatic Cancer Indication
Abraxane sales have been growing fast as Celgene has added new indications. Pancreatic cancer had been an off-label use prior to the new approval.